it-101
Small moleculeexperimental
Clinical trial activity
13 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2008 (NCT01565421)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Hamartoma · Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Rectal Neoplasms · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 2
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- crlx101
- crlx101
- crlx101
- it-101
- it-101
- it-101
- it-101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03531827 | Phase 2 | Oct 5, 2018 | National Cancer Institute (NCI) |
| NCT02769962 | Phase 1/Phase 2 (Phase 2) | May 3, 2016 | National Cancer Institute (NCI) |
| NCT02648711 | Phase 1 | Oct 1, 2015 | NewLink Genetics Inc |
| NCT02389985 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2015 | NewLink Genetics Inc |
| NCT02187302 | Phase 2 | Jul 1, 2014 | NewLink Genetics Inc |
| NCT02010567 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2013 | Cerulean Pharma Inc., University of North Carolina at Chapel Hill |
| NCT01803269 | Phase 2 | Jan 1, 2013 | National Cancer Institute (NCI), University of Chicago |
| NCT01612546 | N/A | Nov 1, 2012 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT01625936 | Phase 1 | Jun 1, 2012 | University of Pennsylvania |
| NCT01652079 | Phase 2 | Apr 1, 2012 | Harvard University |
| NCT01380769 | Phase 2 | Jun 1, 2011 | NewLink Genetics Inc |
| NCT00753740 | Phase 2 | Sep 1, 2008 | NewLink Genetics Inc, New York University, Stanford University |
| NCT01565421 | Phase 2 | Sep 1, 2008 | NewLink Genetics Inc, New York University, Stanford University |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NewLink Genetics Inc | For profit | 6 | 6 | 2 | 2008 |
| National Cancer Institute (NCI) | Government | 4 | 2 | 2 | 2012 |
| New York University | Academic/Hospital | 2 | 0 | 1 | 2008 |
| Stanford University | Academic/Hospital | 2 | 0 | 1 | 2008 |
| Cerulean Pharma Inc. | For profit | 1 | 0 | 1 | 2013 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Chicago | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2012 |
10 organizations
Page 1 / 1